title: Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
abstract: OBJECTIVE
  Tumor infiltrating lymphocytes (TILs) and T regulatory cells (Tregs) have been associated with prognosis in ovarian cancer, but their prognostic significance in ascites has not been studied. We performed a prospective study of T lymphocytes isolated from ascites from patients with ovarian carcinoma and we compared them with the respective populations in blood and tumors.
  
  
  METHODS
  Mononuclear cells from ascites (n=71) and blood were isolated by Ficoll, while tumor lymphocytes (n=20) were obtained upon mechanical dissociation. Phenotypic analysis was performed with flow cytometry. Ascites from 10 patients with cirrhosis was used as control.
  
  
  RESULTS
  Tregs containing CD4(+)CD25(+) cells, NK-T containing CD3(+)CD56(+) cells and CD69 and HLADR expression of CD4 and CD8 lymphocytes were significantly increased in tumor ascites compared to blood and control ascites. A selective accumulation of these populations in the ascites of cancer patients, was suggested by the significantly higher ascites/blood (A/B) ratios in cancer patients but not controls. Cancer cell content in ascites was correlated with CD4(+)CD25(+), CD4(+)CD69(+), CD4(+)HLADR(+) and CD8(+)CD69(+) cells. There was no correlation of lymphocyte populations between ascites and samples from peritoneal metastases. Higher tumor grade was associated with increased A/B CD4(+)CD25(+) ratio and reduced CD3(+)CD56(+) cells, while platinum resistance was associated with reduced A/B CD3(+)CD56(+) ratio.
  
  
  CONCLUSIONS
  There are significant differences of CD3(+)CD56(+) and CD25(+)CD4(+) lymphocytes and increase in lymphocyte activation between blood, ascites and peritoneal metastases from patients with ovarian cancer. The selective accumulation of CD3(+)CD56(+) population in ascites may be a predictive factor for platinum resistance.
authors: Department of Clinical Therapeutics, University of Athens, Greece. abamias@med.uoa.gr <abamias@med.uoa.gr>
authors: A
authors: A
authors: Bamias
authors: M L
authors: ML
authors: Tsiatas
authors: E
authors: E
authors: Kafantari
authors: C
authors: C
authors: Liakou
authors: A
authors: A
authors: Rodolakis
authors: Z
authors: Z
authors: Voulgaris
authors: G
authors: G
authors: Vlahos
authors: T
authors: T
authors: Papageorgiou
authors: O
authors: O
authors: Tsitsilonis
authors: C
authors: C
authors: Bamia
authors: G
authors: G
authors: Papatheodoridis
authors: Ek
authors: E
authors: Politi
authors: A
authors: A
authors: Archimandritis
authors: A
authors: A
authors: Antsaklis
authors: M A
authors: MA
authors: Dimopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000276:immunology / Q000473:pathology; D017252:CD3 Complex / Q000096:biosynthesis / Q000276:immunology*; D019002:CD56 Antigen / Q000096:biosynthesis / Q000276:immunology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000473:pathology
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; D053645:Interleukin-2 Receptor alpha Subunit; D009944:Organoplatinum Compounds